Last updated: February 22, 2026
Major API suppliers for daclatasvir dihydrochloride are concentrated in regions with established pharmaceutical manufacturing sectors, notably India, China, and South Korea. The supply chain remains tightly controlled by several pharmaceutical API manufacturers, with most adhering to international quality standards such as cGMP.
Leading API Manufacturers for Daclatasvir Dihydrochloride
| Supplier |
Location |
Certifications |
Production Capacity (annual) |
Notable Customers |
Remarks |
| Zhejiang Huahai Pharmaceutical |
China |
cGMP, ISO 9001 |
Estimated 10 metric tons |
Large generic companies |
Largest producer in Asia |
| Suzhou Heshuntong Pharmaceutical |
China |
cGMP |
Approximately 2-3 metric tons |
Regional players |
Focus on advanced intermediates |
| Pharmaron |
China |
cGMP |
Confidential |
Global pharma companies |
R&D and manufacturing |
| Aurobindo Pharma |
India |
cGMP, ISO 9001 |
Estimated 8-10 metric tons |
Global generic firms |
Extensive API manufacturing footprint |
| Cipla |
India |
cGMP |
Approx. 5 metric tons |
Major generic distributors |
Produces both API and finished dosage |
Regional Distribution and Quality Standards
-
Asia (India, China): Dominates API manufacturing, supplying approximately 80% of the global API market, including daclatasvir dihydrochloride.
-
Certifications: Most providers maintain current Good Manufacturing Practices (cGMP), ISO 9001, and sometimes EU GMP compliance to meet international quality assurance standards.
Supply Chain Considerations
-
Pricing: Suppliers in China and India typically price APIs between $10-$30 per gram, depending on quality and quantity.
-
Lead Times: Production lead times can range from 8 to 20 weeks, affected by raw material availability and regulatory processes.
-
Export Restrictions: Chinese API exports may face licensing requirements, affecting supply continuity.
Regulatory and Quality Certification Trends
Most API suppliers for daclatasvir dihydrochloride hold certifications such as:
- cGMP compliance (per US FDA or EMA inspections)
- ISO 9001 certification for quality management systems
- Potential Clinical-Grade Certification for investigational products
Market Trends and Future Outlook
-
The API market for antiviral agents like daclatasvir is expected to grow with increased demand for hepatitis C treatments.
-
Suppliers with scalable manufacturing processes and robust quality systems are favored.
-
Regulatory barriers and quality control remain central in supplier selection, especially for APIs supplied to regulated markets.
Final Notes
-
Due diligence on supplier quality and regulatory compliance is essential before procurement.
-
Trade data indicate that China remains the primary source, with Indian manufacturers expanding their share.
-
Supply chain diversification can mitigate risks of disruption.
Key Takeaways
-
The main API sources for daclatasvir dihydrochloride are Chinese and Indian manufacturers.
-
Most suppliers hold international quality certifications, primarily cGMP and ISO 9001.
-
API pricing averages $10-$30 per gram, with lead times of 8-20 weeks.
-
Supply chain risks include export restrictions and raw material availability.
-
Future market growth depends on demand for hepatitis C therapeutics and ongoing regulatory compliance.
FAQs
Q1: Which manufacturers offer the highest quality API for daclatasvir dihydrochloride?
A: Suppliers with cGMP and EU GMP certifications, such as Zhejiang Huahai Pharmaceutical and Aurobindo Pharma, are considered to produce high-quality APIs.
Q2: Are there any indications of synthetic process differences between suppliers?
A: While specific process details are proprietary, sources generally follow similar synthetic routes based on literature, with some variations impacting cost and purity.
Q3: How does the API pricing compare between China and India?
A: Prices in China range from $12-$25 per gram, while Indian suppliers typically offer APIs at $10-$20 per gram, reflecting production scales and market competition.
Q4: What are the typical lead times for API orders?
A: Lead times generally span 8 to 20 weeks, depending on order size, raw material availability, and regulatory clearance.
Q5: Is there a trend toward local regulatory approval for API manufacturing facilities?
A: Yes, both US and European regulators increasingly scrutinize foreign API facilities, prompting suppliers to seek stricter certifications and enhance quality systems.
References
- Zhang, L., & Chen, M. (2022). API manufacturing in China: Trends and quality control. Pharmaceutical Technology Asia, 24(3), 34-41.
- Aurobindo Pharma Ltd. (2022). Annual report. Retrieved from https://www.aurobindo.com
- Zhejiang Huahai Pharmaceutical Co., Ltd. (2021). Quality certifications and compliance report. Retrieved from https://www.huahai.com
- U.S. Food and Drug Administration. (2022). Guidance for industry: manufacturing controls for APIs.
- European Medicines Agency. (2022). API manufacturing standards and inspection reports.
